Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts

Chandrajit P. Raut, Steffan Nawrocki, Laura M. Lashinger, Darren W. Davis, Sanaz Khanbolooki, Henry Xiong, Lee M. Ellis, David J. McConkey

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Previous studies suggest that antagonists of cyclooxygenases 1 and 2 (COX-1, -2) inhibit angiogenesis in tumor xenografts, but the molecular mechanisms involved remain unclear. Here we characterized the effects of non-selective (indomethacin) and selective (NS398, celecoxib) cyclooxygenase inhibitors on parameters of angiogenesis in human pancreatic adenocarcinoma cells. COX-1 expression was constitutive in 9/9 pancreatic cancer cell lines, whereas COX-2 and cytosolic phospholipase A2 (cPLA2) expression were observed in 4/9 cell lines (BxPC3, Capan2, Cfpac1 and L3.6 pl). Production of the COX product, prostaglandin E2, correlated with expression of cPLA2 and COX-2 and was blocked by non-steroidal anti-inflammatory drugs (NSAIDs, indomethacin or NS398). In contrast to the findings of others, neither indomethacin nor NS398 affected tumor cell secretion of angiogenic factors (VEGF, bFGF, IL-8) at concentrations that produced maximal inhibition of PGE2 production, and higher concentrations increased angiogenic factor production. We also studied the effects of celecoxib in orthotopic L3.6 pl xenografts. Immunofluorescence analysis revealed high-level expression of COX-2 in endothelial cells in L3.6 pl xenografts that increased following therapy with celecoxib, whereas the tumor cells expressed uniformly low levels of COX-2. Celecoxib did not decrease tumor-associated VEGF levels in orthotopic human L3.6 pl xenografts, but the drug did decrease tumor microvessel density (MVD) and increase apoptosis in tumor-associated endothelial cells in a dose-dependent fashion. Together, our results demonstrate that the anti-angiogeneic effects of NSAIDs in human pancreatic cancer cells are exerted via direct effects on endothelial cells.

Original languageEnglish (US)
Pages (from-to)1217-1224
Number of pages8
JournalCancer Biology and Therapy
Volume3
Issue number12
StatePublished - Dec 2004
Externally publishedYes

Fingerprint

Celecoxib
Heterografts
Endothelial Cells
Apoptosis
Indomethacin
Cytosolic Phospholipases A2
Neoplasms
Angiogenesis Inducing Agents
Non-Steroidal Anti-Inflammatory Agents
Pancreatic Neoplasms
Dinoprostone
Vascular Endothelial Growth Factor A
Cell Line
Cyclooxygenase 1
Cyclooxygenase Inhibitors
Cyclooxygenase 2
Microvessels
Interleukin-8
Pharmaceutical Preparations
Fluorescent Antibody Technique

Keywords

  • Apoptosis
  • bFGF
  • Celecoxib
  • COX-2
  • IL-8
  • VEGF

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Raut, C. P., Nawrocki, S., Lashinger, L. M., Davis, D. W., Khanbolooki, S., Xiong, H., ... McConkey, D. J. (2004). Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts. Cancer Biology and Therapy, 3(12), 1217-1224.

Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts. / Raut, Chandrajit P.; Nawrocki, Steffan; Lashinger, Laura M.; Davis, Darren W.; Khanbolooki, Sanaz; Xiong, Henry; Ellis, Lee M.; McConkey, David J.

In: Cancer Biology and Therapy, Vol. 3, No. 12, 12.2004, p. 1217-1224.

Research output: Contribution to journalArticle

Raut, CP, Nawrocki, S, Lashinger, LM, Davis, DW, Khanbolooki, S, Xiong, H, Ellis, LM & McConkey, DJ 2004, 'Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts', Cancer Biology and Therapy, vol. 3, no. 12, pp. 1217-1224.
Raut CP, Nawrocki S, Lashinger LM, Davis DW, Khanbolooki S, Xiong H et al. Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts. Cancer Biology and Therapy. 2004 Dec;3(12):1217-1224.
Raut, Chandrajit P. ; Nawrocki, Steffan ; Lashinger, Laura M. ; Davis, Darren W. ; Khanbolooki, Sanaz ; Xiong, Henry ; Ellis, Lee M. ; McConkey, David J. / Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts. In: Cancer Biology and Therapy. 2004 ; Vol. 3, No. 12. pp. 1217-1224.
@article{ab896adfaf1941989cbc374cf4a4fe1a,
title = "Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts",
abstract = "Previous studies suggest that antagonists of cyclooxygenases 1 and 2 (COX-1, -2) inhibit angiogenesis in tumor xenografts, but the molecular mechanisms involved remain unclear. Here we characterized the effects of non-selective (indomethacin) and selective (NS398, celecoxib) cyclooxygenase inhibitors on parameters of angiogenesis in human pancreatic adenocarcinoma cells. COX-1 expression was constitutive in 9/9 pancreatic cancer cell lines, whereas COX-2 and cytosolic phospholipase A2 (cPLA2) expression were observed in 4/9 cell lines (BxPC3, Capan2, Cfpac1 and L3.6 pl). Production of the COX product, prostaglandin E2, correlated with expression of cPLA2 and COX-2 and was blocked by non-steroidal anti-inflammatory drugs (NSAIDs, indomethacin or NS398). In contrast to the findings of others, neither indomethacin nor NS398 affected tumor cell secretion of angiogenic factors (VEGF, bFGF, IL-8) at concentrations that produced maximal inhibition of PGE2 production, and higher concentrations increased angiogenic factor production. We also studied the effects of celecoxib in orthotopic L3.6 pl xenografts. Immunofluorescence analysis revealed high-level expression of COX-2 in endothelial cells in L3.6 pl xenografts that increased following therapy with celecoxib, whereas the tumor cells expressed uniformly low levels of COX-2. Celecoxib did not decrease tumor-associated VEGF levels in orthotopic human L3.6 pl xenografts, but the drug did decrease tumor microvessel density (MVD) and increase apoptosis in tumor-associated endothelial cells in a dose-dependent fashion. Together, our results demonstrate that the anti-angiogeneic effects of NSAIDs in human pancreatic cancer cells are exerted via direct effects on endothelial cells.",
keywords = "Apoptosis, bFGF, Celecoxib, COX-2, IL-8, VEGF",
author = "Raut, {Chandrajit P.} and Steffan Nawrocki and Lashinger, {Laura M.} and Davis, {Darren W.} and Sanaz Khanbolooki and Henry Xiong and Ellis, {Lee M.} and McConkey, {David J.}",
year = "2004",
month = "12",
language = "English (US)",
volume = "3",
pages = "1217--1224",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "12",

}

TY - JOUR

T1 - Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts

AU - Raut, Chandrajit P.

AU - Nawrocki, Steffan

AU - Lashinger, Laura M.

AU - Davis, Darren W.

AU - Khanbolooki, Sanaz

AU - Xiong, Henry

AU - Ellis, Lee M.

AU - McConkey, David J.

PY - 2004/12

Y1 - 2004/12

N2 - Previous studies suggest that antagonists of cyclooxygenases 1 and 2 (COX-1, -2) inhibit angiogenesis in tumor xenografts, but the molecular mechanisms involved remain unclear. Here we characterized the effects of non-selective (indomethacin) and selective (NS398, celecoxib) cyclooxygenase inhibitors on parameters of angiogenesis in human pancreatic adenocarcinoma cells. COX-1 expression was constitutive in 9/9 pancreatic cancer cell lines, whereas COX-2 and cytosolic phospholipase A2 (cPLA2) expression were observed in 4/9 cell lines (BxPC3, Capan2, Cfpac1 and L3.6 pl). Production of the COX product, prostaglandin E2, correlated with expression of cPLA2 and COX-2 and was blocked by non-steroidal anti-inflammatory drugs (NSAIDs, indomethacin or NS398). In contrast to the findings of others, neither indomethacin nor NS398 affected tumor cell secretion of angiogenic factors (VEGF, bFGF, IL-8) at concentrations that produced maximal inhibition of PGE2 production, and higher concentrations increased angiogenic factor production. We also studied the effects of celecoxib in orthotopic L3.6 pl xenografts. Immunofluorescence analysis revealed high-level expression of COX-2 in endothelial cells in L3.6 pl xenografts that increased following therapy with celecoxib, whereas the tumor cells expressed uniformly low levels of COX-2. Celecoxib did not decrease tumor-associated VEGF levels in orthotopic human L3.6 pl xenografts, but the drug did decrease tumor microvessel density (MVD) and increase apoptosis in tumor-associated endothelial cells in a dose-dependent fashion. Together, our results demonstrate that the anti-angiogeneic effects of NSAIDs in human pancreatic cancer cells are exerted via direct effects on endothelial cells.

AB - Previous studies suggest that antagonists of cyclooxygenases 1 and 2 (COX-1, -2) inhibit angiogenesis in tumor xenografts, but the molecular mechanisms involved remain unclear. Here we characterized the effects of non-selective (indomethacin) and selective (NS398, celecoxib) cyclooxygenase inhibitors on parameters of angiogenesis in human pancreatic adenocarcinoma cells. COX-1 expression was constitutive in 9/9 pancreatic cancer cell lines, whereas COX-2 and cytosolic phospholipase A2 (cPLA2) expression were observed in 4/9 cell lines (BxPC3, Capan2, Cfpac1 and L3.6 pl). Production of the COX product, prostaglandin E2, correlated with expression of cPLA2 and COX-2 and was blocked by non-steroidal anti-inflammatory drugs (NSAIDs, indomethacin or NS398). In contrast to the findings of others, neither indomethacin nor NS398 affected tumor cell secretion of angiogenic factors (VEGF, bFGF, IL-8) at concentrations that produced maximal inhibition of PGE2 production, and higher concentrations increased angiogenic factor production. We also studied the effects of celecoxib in orthotopic L3.6 pl xenografts. Immunofluorescence analysis revealed high-level expression of COX-2 in endothelial cells in L3.6 pl xenografts that increased following therapy with celecoxib, whereas the tumor cells expressed uniformly low levels of COX-2. Celecoxib did not decrease tumor-associated VEGF levels in orthotopic human L3.6 pl xenografts, but the drug did decrease tumor microvessel density (MVD) and increase apoptosis in tumor-associated endothelial cells in a dose-dependent fashion. Together, our results demonstrate that the anti-angiogeneic effects of NSAIDs in human pancreatic cancer cells are exerted via direct effects on endothelial cells.

KW - Apoptosis

KW - bFGF

KW - Celecoxib

KW - COX-2

KW - IL-8

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=22344443289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22344443289&partnerID=8YFLogxK

M3 - Article

C2 - 15477758

AN - SCOPUS:22344443289

VL - 3

SP - 1217

EP - 1224

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 12

ER -